Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results.
The purpose of this study was to clarify the actual therapeutic potential of a new transdermal drug delivery system (electromotive drug administration; EMDA) for selected patients with Peyronie's disease. Forty patients with Peyronie's disease were treated by electromotive administration of the 3-drug association orgotein-dexamethasone-lidocaine in a double-blind, placebo-controlled, partial crossover study (study 1). Another 25 patients were treated by EMDA with a combination of verapamil-dexamethasone in an uncontrolled study (study 2). Treatment sessions lasted 20 minutes each and took place 3 times a week for 3 weeks with a current of 3 mA. Patients were assessed before treatment and at 1- and 3-month follow-up examinations. Assessments were based on sexual history, physical examination, and dynamic color Doppler ultrasonographic results. Adverse effects of EMDA were not reported. In study 1, the clinical results observed after treatment proved to be significantly better than those of the placebo. Penile pain disappeared in all patients in both studies. Penile lesion (nodule or plaque) either disappeared or significantly improved in 79% and 90% of patients treated by the 3- and 2-drug association, respectively. The improvement of penile deformity also was notable although it did not match the effect observed on penile nodules or plaque (62% and 88%, in studies 1 and 2, respectively). In both studies, more than 80% of patients reported a definite amelioration of penile rigidity, which paralleled the improvement of penile dynamic color Doppler ultrasonographic parameters. Overall, the combination of verapamil-dexamethasone achieved better clinical results than the 3-drug combination. Electromotive drug administration is a novel technique capable of safely achieving satisfactory results in selected patients with Peyronie's disease not only in terms of improvement of patient's symptoms but also due to the reduced need for penile surgery.
Montorsi
F
F
Institute of Human Anatomy, School of Medicine, University of Milan, Italy.
Salonia
A
A
Guazzoni
G
G
Barbieri
L
L
Colombo
R
R
Brausi
M
M
Scattoni
V
V
Rigatti
P
P
Pizzini
G
G
D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D000779:Anesthetics, Local / Q000008:administration & dosage / Q000627:therapeutic use; D018592:Cross-Over Studies; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004586:Electrophoresis; D018274:Electroporation; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007478:Iontophoresis; D008012:Lidocaine / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008667:Metalloproteins / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D010146:Pain / Q000503:physiopathology; D010411:Penile Induration / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D018615:Ultrasonography, Doppler, Color; D014700:Verapamil / Q000008:administration & dosage / Q000627:therapeutic use
D000779:Anesthetics, Local; D005938:Glucocorticoids; D008667:Metalloproteins; D003907:Dexamethasone; D008012:Lidocaine; D014700:Verapamil; C005180:orgotein